We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Experimental Monoclonal Antibody-Based Drug Lowers LDL-cholesterol Levels

By LabMedica International staff writers
Posted on 13 Jun 2012
An experimental cholesterol-lowering drug was found to augment the action of statins to further lower LDL-cholesterol (low-density lipoprotein – cholesterol) levels in patients with elevated cholesterol due to the hereditary condition heterozygous familial hypercholesterolemia.

The drug REGN727 was the result of collaboration between the American biopharmaceutical company Regeneron (Tarrytown, NY, USA) and the French healthcare giant Sanofi (Paris, France). REGN727 is a monoclonal antibody specific for the enzyme proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9).

PCSK9 belongs to the proteinase K subfamily of the secretory subtilase family. The protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoproteins, which could lead to hypercholesterolemia.

A paper describing a clinical trial in which 77 patients with heterozygous familial hypercholesterolemia were treated with REGN727 plus high-dose statins, with or without ezetimibe or with only the statins (with or without ezetimibe) was published in the May 26, 2012, online edition of the journal the Lancet.

Results of the study revealed that after 12 weeks, patients taking REGN727 saw their cholesterol levels reduced by between 28.9% and 67.9% depending on their dosing regimen, compared with 10.7% among those taking a dummy treatment.

The investigators concluded, “REGN727 was well tolerated and achieved substantial further LDL-C reduction in patients with heterozygous familial hypercholesterolemia and elevated LDL-C treated with high-dose statins, with or without ezetimibe.”

Related Links:

Regeneron
Sanofi




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Monkeypox Test
Monkeypox Virus Rapid Antibody Test
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries